Prosigna Package Insert
To download the Prosigna Package Insert, select a language from the options below:
nCounter® Dx Analysis System User Manual
To download the nCounter Dx Analysis System User Manual, select a language from the options below:
Prosigna Product Data Sheet
Click here to download the Prosigna Product Data Sheet.
List of publications
TransATAC Clinical Verification Study
Click here to access the TransATAC clinical verification study article, available through Journal of Clinical Oncology.
ABCSG-8 Clinical Validation Study
Click here to access the ABCSG-8 clinical validation study article.
Analytical Validation Study
Click here to access the analytical validation study, available through BMC Cancer.
Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II or IIIA) early-stage breast cancer to be treated with adjuvant endocrine therapy.
© 2014-2017 NanoString Technologies, Inc. All rights reserved. NanoString, the NanoString Technologies logo, nCounter, Prosigna and the Prosigna logo are trademarks and/or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.